ArticleMayo Clinic proceedings2020
Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients.
Article in Mayo Clinic proceedings, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 270 papers, 16 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Convalescent Plasma for Severe COVID-19 Patients: a Randomized, Open-label, Phase 3 Trial
COVID-19 Convalescent Plasma Therapy
Who cites it
270 citing papers in PubMed, 16 syntheses or guidelines pooled it, 430 citations in OpenAlex.
- Effect of convalescent plasma transfusion on outcomes of coronavirus disease 2019: a meta-analysis with trial sequential analysis.Journal of anesthesia · 2023Pooled it
- Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023Pooled it
- Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023Pooled it
- Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma.Annals of internal medicine · 2022Guideline
- Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients.Nature communications · 2022Pooled it
- Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Systematic review and meta-analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (COVID-19): Evidence-base for practise and implications for research.Transfusion medicine (Oxford, England) · 2021Pooled it
- Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis.Critical care medicine · 2021Pooled it
- Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics.Reviews in medical virology · 2021Pooled it
- Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline.Clinical and molecular hepatology · 2021Guideline
- Pooled it
- Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2021Pooled it
- The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis.Mayo Clinic proceedings · 2021Pooled it
- Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.JMIR public health and surveillance · 2021Pooled it
- Pooled it
- Convalescent plasma may be a possible treatment for COVID-19: A systematic review.International immunopharmacology · 2021Pooled it
- Convalescent Plasma for Covid-19-Induced ARDS in Mechanically Ventilated Patients.The New England journal of medicine · 2023Trial
- Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial.BMC infectious diseases · 2022Trial
- Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial).BMJ open · 2022Trial
- Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.European journal of internal medicine · 2022Trial
210 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
40 authors at 10 institutions in 1 country.
Funding
Abstract
objectiveTo provide an update on key safety metrics after transfusion of convalescent plasma in hospitalized coronavirus 2019 (COVID-19) patients, having previously demonstrated safety in 5000 hospitalized patients. PATIENTS AND
methodsFrom April 3 to June 2, 2020, the US Food and Drug Administration Expanded Access Program for COVID-19 convalescent plasma transfused a convenience sample of 20,000 hospitalized patients with COVID-19 convalescent plasma.
resultsThe incidence of all serious adverse events was low; these included transfusion reactions (n=78; <1%), thromboembolic or thrombotic events (n=113; <1%), and cardiac events (n=677, ~3%). Notably, the vast majority of the thromboembolic or thrombotic events (n=75) and cardiac events (n=597) were judged to be unrelated to the plasma transfusion per se. The 7-day mortality rate was 13.0% (12.5%, 13.4%), and was higher among more critically ill patients relative to less ill counterparts, including patients admitted to the intensive care unit versus those not admitted (15.6 vs 9.3%), mechanically ventilated versus not ventilated (18.3% vs 9.9%), and with septic shock or multiple organ dysfunction/failure versus those without dysfunction/failure (21.7% vs 11.5%).
conclusionThese updated data provide robust evidence that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19, and support the notion that earlier administration of plasma within the clinical course of COVID-19 is more likely to reduce mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.